Immunoproteasomes edit tumors, which then escapes immune recognition

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• The Major Histocompatibility Complex (MHC) region contains genes, many induced by Interferon-gamma (IFN-γ).
• IFN-γ influences antigen processing and presentation to T cells, involving proteases and their activators.
• The efficacy of cancer immunotherapies targeting tumor antigens can be limited by antigen processing inefficiencies.

Purpose of the Study:

• To investigate the role of IFN-γ-inducible proteases in the inefficient presentation of the MART-1(26-35) epitope in melanoma.
• To understand how specific proteases affect the generation and degradation of T-cell targeted tumor antigens.

Main Methods:

• Analysis of the proteolytic activities of IFN-γ-inducible enzymes: β2i/MECL-1, proteasome activator 28 (PA28), and ERAP-1.
• Assessment of the impact of these enzymes on the processing and presentation of the MART-1(26-35) epitope.

Main Results:

• β2i/MECL-1 and PA28 were found to impede the liberation of MART-1(26-35) from its precursor protein.
• ERAP-1 was shown to degrade the MART-1(26-35) epitope, further contributing to presentation inefficiency.
• These proteolytic activities collectively limit the effectiveness of MART-1/Melan-A-targeted immunotherapy in melanoma.

Conclusions:

• Inefficient presentation of tumor antigens, due to proteolytic activities of IFN-γ-inducible enzymes, can limit cancer immunotherapy success.
• A thorough understanding of T-cell targeted tumor antigens and the proteases involved in epitope generation or destruction is critical for enhancing cancer immunotherapy.